Compelling and statistically significant data for 1st line HNSC (TACTI-003) or/and 1st line NSCLC (TACTI-002).
Efficacy - Must be at least good as chemo/Keytruda SOC. Duration of response must be better and less toxic (the latter is a given)
TACTI-Mel may be revisited but probably not until above is completed and Merck have made a play.
JPMorgan conference, page-18
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.8¢ |
Change
-0.003(0.83%) |
Mkt cap ! $443.0M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 29.5¢ | $839.4K | 2.780M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 484273 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 386894 | 27 |
View Market Depth
| Last trade - 13.28pm 17/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |